CMS Administrator Dr. Mehmet Oz announced earlier this year that eligible Medicare Part D beneficiaries will be able to access select GLP-1 obesity medicines for $50 per month, starting July 1. The program, called the Medicare GLP-1 Bridge, will run through the end of 2027 and include Wegovy, Zepbound, and Foundayo when used for weight reduction.
Obesity affects millions of seniors and Americans with long-term disabilities, raising their risk of diabetes, heart disease, sleep apnea, and other costly conditions. The program represents an expansion of coverage that historically excluded obesity medications under Medicare.
What the Left Is Saying
Progressive health advocates have largely welcomed the GLP-1 Bridge as a step toward expanding access to transformative weight-loss treatments. They argue that Medicare rules had not kept pace with medical innovation, locking out patients who need these medications.
Patient advocacy groups representing individuals with obesity and related conditions say the $50 monthly copay removes a significant financial barrier for seniors who have struggled to afford these drugs. Some progressive economists note that the program could reduce long-term healthcare costs by preventing obesity-related emergencies and hospitalizations.
Democratic lawmakers have pointed to the Bridge as evidence that targeted government programs can improve health outcomes. They argue that without intervention, pharmaceutical companies would continue charging prices that put these medications out of reach for many Medicare beneficiaries who need them most.
What the Right Is Saying
Conservative economists and free-market advocates caution against viewing the bridge program as a template for broader price-setting. They emphasize that the $50 copay is subsidized by taxpayers and represents a temporary access program, not market-based pricing.
Health economists from conservative think tanks argue that sustainable affordability comes from competition, direct-to-consumer sales, and pressure on supply chain middlemen rather than government pricing mechanisms. They point to recent price reductions in the self-pay market as evidence that competition is already driving down costs.
Some Republican policy analysts have raised concerns about Most-Favored-Nation drug pricing proposals, warning that importing foreign price controls could discourage investment in future medical innovation. They argue that today's discounts could come at the cost of tomorrow's cures if the government turns every breakthrough into a price-setting exercise.
What the Numbers Show
According to CMS, manufacturers will provide eligible GLP-1 drugs under the Bridge program at a net price of $245 per monthly supply. The program operates outside the normal Part D payment flow, with pharmacies collecting the $50 copay from patients and a central processor handling payments.
In 2024, Eli Lilly launched Zepbound single-dose vials through a self-pay channel at $399 per month for the 2.5 mg dose and $549 per month for the 5 mg dose. By the end of 2025, consumer prices in this direct market fell by up to 27 percent.
NovoCare Pharmacy began offering Wegovy to cash-paying patients at $499 per month, with discounts down to $199 per month for the first two monthly fills, then $349 after that. More companies are entering the obesity treatment market, increasing competition and options for patients.
The Bottom Line
The Medicare GLP-1 Bridge offers immediate relief for Part D beneficiaries who need access to obesity treatments now. The program operates as a temporary subsidy, with manufacturers providing drugs at reduced net prices while taxpayers cover the difference between patient copays and actual costs.
What happens after 2027 remains unclear. Policymakers on both sides will be watching whether the bridge becomes permanent, whether it expands to other populations, or whether market competition renders such programs unnecessary. The debate over GLP-1 pricing reflects broader tensions between expanding access and preserving incentives for pharmaceutical innovation.